EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact of headache frequency and preventive treatment failure on quality of life, disability, and direct and indirect costs among individuals with episodic migraine in the United States

David W Dodick iD, Michael L Reed, Lulu Lee, Bridget L Balkaran, Kandavadivu Umashankar, Mousam Parikh, Pranav Gandhi, Dawn C Buse

Headache: The Journal of Head and Face Pain · 2024

DOI: 10.1111/head.14684 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Headache: The Journal of Head and Face Pain, 2024. Verfasst von David W Dodick und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Quality of Life, Treatment Failure. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Allergan (prior to its acquisition by AbbVie), AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate unmet needs among individuals with episodic migraine (EM) in the United States (US).

Background

Data are limited on the impact of headache frequency (HF) and preventive treatment failure (TF) on the burden of migraine in the US.

Methods

A retrospective, cross‐sectional analysis of 2019 National Health and Wellness Survey (NHWS) data was conducted from an opt‐in online survey that identified respondents (aged ≥18 years) in the US with self‐reported physician‐diagnosed migraine. Participants were stratified by HF (low: 0–3 days/month; moderate‐to‐high: 4–14 days/month) and prior preventive TF (preventive naive; 0–1 TF; ≥2 TFs). Comparisons were conducted between preventive TF groups using multivariable regression models controlling for patient demographic and health characteristics.

Results

Among individuals with moderate‐to‐high frequency EM, the NHWS identified 397 with ≥2 TFs, 334 with 0–1 TF, and 356 as preventive naive. The 36‐item Short‐Form Health Survey (version 2) Physical Component Summary scores were significantly lower among those with ≥2 TFs, at a mean (standard error [SE]) of 41.4 [0.8] versus the preventive‐naive 46.8 [0.9] and 0–1 TF 44.5 [0.9] groups; p < 0.001 for both). Migraine Disability Assessment Scale scores were significantly higher in the ≥2 TFs, at a mean (SE) of 37.7 (3.9) versus preventive‐naive 26.8 (2.9) ( p < 0.001) and 0–1 TF 30.1 (3.3) ( p = 0.011) groups. The percentages of time that respondents experienced absenteeism (mean [SE] 21.6% [5.5%] vs. 13.4% [3.6%]; p = 0.022), presenteeism (mean [SE] 55.0% [8.3%] vs. 40.8% [6.5%]; p = 0.015), overall work impairment (mean [SE] 59.4% [5.6%] vs. 45.0% [4.4%]; p < 0.001), and activity impairment (mean [SE] 56.8% [1.0%] vs. 44.4% [0.9%]; p < 0.001) were significantly higher in the ≥2 TFs versus preventive‐naive group. Emergency department visits (preventive‐naive, p = 0.006; 0–1 TF, p = 0.008) and hospitalizations ( p < 0.001 both) in the past 6 months were significantly higher in the ≥2 TFs group. Direct and indirect costs were significantly higher in the ≥2 TFs (mean [SE] $24,026 [3460]; $22,074 [20]) versus 0–1 TF ($10,897 [1636]; $17,965 [17]) and preventive‐naive ($11,497 [1715]; $17,167 [17]) groups ( p < 0.001 for all). Results were similar in the low‐frequency EM group.

Conclusions

In this NHWS analysis, individuals with more prior preventive TFs experienced significantly higher humanistic and economic burden regardless of HF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersQuality of LifeTreatment FailureHumansMaleFemaleUnited StatesAdultMiddle AgedRetrospective StudiesCross-Sectional StudiesCost of IllnessYoung AdultHealth SurveysAdolescentPersons with Disabilities

Stichwörter der Autor:innen

United Statescostshealth care resource usemigrainequality of lifetreatment failure

Autor:innen und Institutionen

  • Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA.
  • Vedanta Research, Chapel Hill, North Carolina, USA.
  • Cerner Enviza, Kansas City, Missouri, USA.
  • AbbVie, Florham Park, New Jersey, USA.
  • Albert Einstein College of Medicine, Bronx, New York, USA.

ORCID-Profile: David W Dodick

Förderung

  • Allergan (prior to its acquisition by AbbVie)
  • AbbVie

Zitieren

APA

Dodick, D. W., Reed, M. L., Lee, L., Balkaran, B. L., Umashankar, K., Parikh, M., Gandhi, P., & Buse, D. C. (2024). Impact of headache frequency and preventive treatment failure on quality of life, disability, and direct and indirect costs among individuals with episodic migraine in the United States. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14684

Vancouver

Dodick DW, Reed ML, Lee L, Balkaran BL, Umashankar K, Parikh M, et al. Impact of headache frequency and preventive treatment failure on quality of life, disability, and direct and indirect costs among individuals with episodic migraine in the United States. Headache: The Journal of Head and Face Pain. 2024. doi:10.1111/head.14684

BibTeX
@article{Dodick2024,
  author = {Dodick, David W and Reed, Michael L and Lee, Lulu and Balkaran, Bridget L and Umashankar, Kandavadivu and Parikh, Mousam and Gandhi, Pranav and Buse, Dawn C},
  title = {Impact of headache frequency and preventive treatment failure on quality of life, disability, and direct and indirect costs among individuals with episodic migraine in the United States},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2024},
  doi = {10.1111/head.14684}
}
Kostenlos starten →